[Current topics for the sphingolipid-mediated signaling pathway].
Sun
Y
Y
sunyidi@pharm.kyoto-u.ac.jp
Tanoue
D
D
Kozutsumi
Y
Y
D000217:Acyltransferases / Q000037:antagonists & inhibitors; D000818:Animals; D002453:Cell Cycle / Q000187:drug effects; D003001:Cloning, Molecular; D004351:Drug Resistance / Q000235:genetics; D004705:Endocytosis; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology; D038362:Glycogen Synthase Kinase 3; D006801:Humans; D011505:Protein-Tyrosine Kinases / Q000502:physiology; D012441:Saccharomyces cerevisiae / Q000166:cytology / Q000235:genetics; D029701:Saccharomyces cerevisiae Proteins; D051102:Serine C-Palmitoyltransferase; D015398:Signal Transduction / Q000502:physiology*; D013107:Sphingolipids / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000502:physiology*
D005229:Fatty Acids, Monounsaturated; D029701:Saccharomyces cerevisiae Proteins; D013107:Sphingolipids; D000217:Acyltransferases; C495089:SPTLC2 protein, human; D051102:Serine C-Palmitoyltransferase; D011505:Protein-Tyrosine Kinases; D038362:Glycogen Synthase Kinase 3; C068124:MCK1 protein, S cerevisiae; C001996:thermozymocidin